GlassScriptPhysician profile
Adair A Laboy
NPI 1952335481
$2,488.96
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $209 · 2021: $329 · 2022: $447 · 2023: $435 · 2024: $163 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $814.10 | 2019-2025 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $460.92 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $269.14 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $211.42 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.73 | 2019 | |
| Mallinckrodt Hospital Products INC. | $117.10 | 2022-2023 | Acthar |
| Boston Scientific Corporation | $101.67 | 2021 | |
| Vifor Pharma, INC. | $99.80 | 2019 | |
| Abbvie INC. | $99.55 | 2020 | |
| Amgen INC. | $48.76 | 2019 | |
| Bayer Puerto Rico INC. | $37.60 | 2023 | Kerendia |
| Ani Pharmaceuticals, INC. | $25.00 | 2024 | Purified Cortrophin Gel |
| Pbg Puerto Rico LLC | $20.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.17 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adair Laboy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.